necessarily require BHV-1-specific signals. This raises the possibility of targeting heterologous polypeptides to the viral envelope, which might enable the construction of BHV-1 recombinants with new biological properties and the development of improved BHV-1-based live and inactivated vector vaccines.
Bovine herpesvirus 1 (BHV-1), a member of the subfamily Alphaherpesvirinae with a double-stranded DNA genome of approximately 136 kbp, causes infectious rhinotracheitis and infectious pustular vulvovaginitis as the most common clinical symptoms in cattle (27, 34, 39) . Vaccination with attenuated live viruses or inactivated virions is widely used to control the disease and to reduce the concomitant financial losses. As with other large DNA viruses, interest exists in the use of recombinant BHV-1 as an improved live vaccine against BHV-1 infection (1, 21, 42) or as a vector for bi-or multivalent vaccines against BHV-1 and additional bovine pathogens (17, 18) . To date, incorporation of heterologous genes into the genome of BHV-1 has concentrated mainly on the expression of the procaryotic lacZ gene to identify essential and nonessential genes or as a reporter gene for analytical studies (3, 8, 12, 15, 20, 29, 37, 38, 45) . Recently, BHV-1 has been used to express biologically active bovine interleukins (21, 32) and glycoproteins of pseudorabiesvirus (19, 31) . However, expression of RNA virus-encoded proteins by BHV-1 has not been published so far. Remarkably, expression of genes from cytoplasmreplicating viruses by other herpesviruses of mammals has only rarely been reported (5, 43) .
Attempts to express the fusion glycoprotein F and the at-tachment glycoprotein G of bovine respiratory syncytial virus (BRSV), a pneumovirus of the family Paramyxoviridae which is also prevalent worldwide and causes severe respiratory disease in young calves similar to the disease caused by human respiratory syncytial virus in children (4), were not successful (13, 33) . Although the cDNA fragments encoding the respective glycoproteins were flanked by transcription control elements that are active in the genomic context of BHV-1 (21) , no BRSV-specific transcripts were detected in cells infected with the BHV-1 recombinants (13) (see below). We therefore assumed that RNAs containing the authentic BRSV sequences were unstable in the nuclei of infected cells. To test this assumption, the BHV-1 glycoprotein D (gD) codon usage preferences (13, 40) were used to construct a modified open reading frame (ORF) encoding the BRSV G glycoprotein by chemically synthesized oligonucleotides.
In this report, we show that expression of the attachment glycoprotein G of BRSV (BRSV G glycoprotein), a type II membrane glycoprotein (36, 44) , by BHV-1 was dependent on the modification of the base composition of the ORF encoding BRSV G glycoprotein, that virions produced by the recombinant contained the BRSV G glycoprotein, and that the presence of this protein in the viral envelope does not significantly interfere with the infectivity of BHV-1. Our findings suggest that RNA viruses which replicate in the cytoplasm can contain sequences or sequence elements that lead to instability of transcripts within the nucleus.
MATERIALS AND METHODS
Cell culture and viruses. BHV-1 strain Schönböken (BHV-1/Schö) was obtained from O. C. Straub (Federal Research Centre for Virus Diseases of Animals, Tübingen, Germany) and propagated on Madin-Darby bovine kidney cell clone Bu100 (MDBK-Bu100; kindly provided by W. Lawrence and L. Bello, University of Pennsylvania, Philadelphia, Pa.). The cells were grown in Dulbecco's minimum essential medium supplemented with 5% fetal calf serum (FCS), 100 U of penicillin per ml, 100 g of streptomycin per ml, and 0.35 mg of L-glutamine per ml. The gD-negative mutant BHV-1/80-221 was propagated on the constitutively gD-expressing cell line BU-Dorf as described previously (38) .
Construction and cloning of the BRSV G syn ORF. Oligonucleotides were synthesized in a Biosearch 8700 instrument and purified by gel electrophoresis. Complementary oligonucleotides were mixed in equal molar amounts in 10 mM Tris-HCl (pH 7.5), boiled for 5 min, and slowly cooled to room temperature. All the cloning procedures were performed by established methods (35) . The following double-stranded DNA fragments were generated (restriction enzyme cleavage sites used for cloning are shown in boldface type). Fragment 1 was ligated into plasmid vector pUC18 after cleavage with AatII and BamHI. In the resulting plasmid, pF1, the AatII cleavage site of pUC18 was destroyed. Plasmid pF1 was cleaved with NruI and BamHI and received fragment 2 to produce pF2, into which fragment 3 was ligated after digestion with AatII and BamHI to yield pF1-3. In parallel, pUC19 DNA was cleaved with HindIII and PstI, fragment 7 was inserted, and the resulting plasmid, pF7, was cleaved with PstI and SpeI and received fragment 6 to generate pF6. Plasmid pF6 was incubated with PstI and BstEII, and fragment 5 was inserted. The plasmid obtained, pF5, was treated with PstI and ClaI, and fragment 4 was integrated, resulting in plasmid pF4. Plasmid pF4 was cleaved with XbaI, blunt ended with Klenow polymerase, and recleaved with AflII. Into this DNA, the HindIII-AflII fragment of pF1-3 was ligated after blunt ending of the HindIII site. The resulting plasmid, pBRSVGsyn, contained the reconstructed BRSV G ORF flanked by EcoRI cleavage sites.
Other plasmid constructions. Plasmid pRSV02 (kindly provided by Paul Sondermejer, Intervet International, Boxmeer, The Netherlands), which contains a cDNA fragment encoding the BRSV G glycoprotein, was cleaved with BglII. A 770-bp fragment, which encompasses codons 1 to 257 of the BRSV G ORF, was ligated into plasmids pROMie and pROMe (21) cleaved with BglII followed by insertion of a synthetic DNA fragment, obtained by hybridizing oligonucleotides 5Ј-CATGCACACCTCCATATAA-3Ј and 5Ј-CATGTTATATGGAGGTGTG-3Ј, as described above, into a single NcoI cleavage site to provide a stop codon. The resulting plasmids, in which codon 259 was changed from CAA (encoding glutamine) to ATG (encoding methionine), were named pROMieG ori and pROMeG ori , respectively.
To construct recombination plasmid pROMeG syn , plasmid pROMe was cleaved with BglII, blunt ended with Klenow polymerase, and used for the insertion of the synthetic G ORF, isolated from plasmid pBRSVG syn after cleavage with EcoRI and blunt ending with Klenow polymerase. For synthesis of cRNA, the same fragment was integrated into the BglII-cleaved and blunt-ended plasmid vector pSP73 (Promega, Heidelberg, Germany) to give plasmid pSPG syn . For in vitro transcription of the BRSV G ori ORF, a blunt-ended ClaI fragment encompassing this ORF in plasmid pROMeG ori was inserted into EcoRVcleaved pSP73. The resulting plasmid was designated pSPG ori . The correctness and orientation of the BRSV G ORFs were determined by dideoxy sequencing, which showed that the 5Ј ends of the G ori and G syn ORFs were placed adjacent to the T7 or SP6 promoter, respectively.
In vitro transcription and translation. Plasmids pSPG ori and pSPG syn were linearized with BglII and HindIII, respectively, and cRNA was transcribed by T7 or SP6 RNA polymerase in the presence of the cap analog m 7 GpppG as specified by the manufacturer (Boehringer GmbH, Mannheim, Germany). In vitro translation of the cRNAs was performed in the presence of 60 Ci of [ 35 S]methionine per reaction mixture as recommended by the supplier (Promega). Labeled proteins were visualized by fluorography after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10% polyacrylamide) as described previously (16) .
RNA isolation, Northern blot hybridization, and nuclear runoff analysis. Whole-cell RNA and cytoplasmic RNA was isolated as described previously (14, 35) . Glyoxal-treated RNA (5 g) was separated in 1% formaldehyde gels, transferred to nitrocellulose filters, and hybridized to 32 P-labeled DNA by established procedures (14, 35) . Nuclear runoff transcription assays were performed by the method of Greenberg and Ziff (11) . Labeled RNA was hybridized to equimolar (1.5 pmol) amounts of plasmid DNA dotted onto nitrocellulose filters with a dot blot device (Schleicher & Schüll, Dassel, Germany). Bound radioactivity was visualized by autoradiography and quantitated by Cerenkov counting.
Antibodies and sera. BRSV G glycoprotein-specific monoclonal antibody (MAb) 20 and MAb 57 and the polyclonal serum directed against BHV-1 gD are described elsewhere (8, 9, 23) . The anti-VacG syn serum was raised in rabbits infected with a recombinant vaccinia virus expressing the G syn ORF under control of the p7.5 promoter. The rabbits were inoculated with 5 ϫ 10 7 PFU and bled 4 weeks after a booster immunization with 5 ϫ 10 7 PFU given 1 week after the initial infection. The BRSV-neutralizing titer was 1:80 in the presence of complement. Polyclonal anti-BRSV hyperimmune serum 2106 was raised in gnotobiotic calves after repeated inoculation with BRSV and had a BRSVneutralizing titer of 1:10,000 in the absence of complement (10) .
Western blotting and immunoprecipitation. For Western blotting (immunoblotting), cells or purified virions were lysed in sample buffer. For analysis of secreted proteins, infected cells were cultured with Dulbecco's minimal essential medium lacking FCS. Culture supernatants were clarified by ultracentrifugation and, after addition of 3 volumes of ice-cold acetone, incubated for 15 min at Ϫ70°C. Precipitates were collected by centrifugation, air dried at room temperature, and resuspended in sample buffer. The proteins were separated and immunodetected as described previously (37) . [ 35 S]methionine-labeled proteins were immunoprecipitated from purified virions as described by Fehler et al. (8) . The apparent molecular masses of proteins in SDS-polyacrylamide gels were determined from standard curves with 14 C-methylated protein molecular mass standards (Amersham, Braunschweig, Germany) or prestained protein molecular mass standards (Gibco BRL, Eggenstein, Germany).
Deglycosylation reactions. Virions, purified as described previously (8), were resuspended in 0.5% Nonidet P-40 in phosphate-buffered saline (PBS) and incubated overnight at 37°C with 0.4 U of N-glycosidase F (Boehringer), 1 mU of neuraminidase (Boehringer) or 1 mU of neuraminidase and 1.5 mU of Oglycosidase (Boehringer). Immunoprecipitated proteins were incubated with the respective enzymes under conditions recommended by the supplier.
Virus neutralization assays. Samples (approximately 200 PFU) of wild-type and recombinant BHV-1 strains were incubated with serial dilutions of MAbs or sera in a final volume of 100 l of cell culture medium containing 20% FCS with or without 5% normal rabbit serum as a source of complement and plated onto MDBK-Bu100 cells after 1 h at 37°C. The cultures were overlaid with semisolid medium 2 h later, and plaques were counted 2 to 3 days after infection. The percent neutralization-resistant infectivity was calculated from the results with controls incubated without antibody.
Infection of cells for indirect immunofluorescence. MDBK-Bu100 cell cultures were infected with approximately 100 PFU and overlaid with semisolid medium. After the development of plaques, the cultures were fixed with 3% paraformaldehyde in PBS and sequentially incubated with appropriate dilutions of MAbs or sera and 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF)-conjugated goat anti-species immunoglobulin G (Dianova, Hamburg, Germany). 
RESULTS
Rationale for synthesis of a modified BRSV G glycoprotein ORF. To express the BRSV G glycoprotein by recombinant BHV-1, recombination plasmid pROMeG ori , which contains a cDNA fragment encompassing the BRSV G glycoprotein ORF under control of the murine cytomegalovirus (MCMV) early 1 promoter ( Fig. 1 ), was cotransfected with purified BHV-1/80-221 DNA into MDBK cells and the progeny virus was serially diluted and plated on MDBK cells. Since the ORF encoding the essential gD is replaced by a lacZ expression cassette in BHV-1/80-221 (8), only viruses which have acquired the gD ORF by replacement of the lacZ cassette by the insert of the recombination plasmid should be able to replicate on noncomplementing cells (21) . Virus from plaques that did not stain blue under a Bluo-Gal-containing agarose overlay were again subjected to titer determination on MDBK cells, and isolates which produced only "white" plaques were plaque purified once more and characterized further (see Fig. 4 ). Analysis of MDBK cells infected with the resulting recombinant BHV-1/eG ori gave no indication of BRSV G glycoprotein expression by indirect immunofluorescence (see Fig. 7 ), and no stable transcripts were detected within cytoplasmic RNA (data not shown) or whole-cell RNA (see Fig. 5 ). BRSV G glycoprotein expression was also not detected in transient-expression experiments with plasmid pROMieG ori (Fig. 1 ) in which the BRSV G glycoprotein ORF is under the control of the MCMV immediate-early 1 enhancer/promoter element (data not shown). In vitro translation of mRNA, transcribed in vitro from pSPG ori , resulted in synthesis of a polypeptide whose apparent molecular mass of 31 kDa (Fig. 2 , lane 2) was in good agreement with the calculated size of 29 kDa (24). This result indicated that mRNA from the BRSV G ori ORF contained within pROMeG ori has the potential to direct protein synthesis, and we assumed that the failure to detect BRSV G glycoprotein-specific gene products was due to instability of BRSV G glycoprotein transcripts in the nuclei of BHV-1/eG ori -infected cells. Therefore, a modified ORF encoding the BRSV G glycoprotein ( Fig. 3 ) was chemically synthesized, isolated from plasmid pBRSVG syn , and inserted into pROMe and pSP73. The resulting plasmids were named pROMeG syn and pSPG syn , respectively, and RNA transcribed from pSPG syn directed the synthesis of a 31-kDa protein in a rabbit reticulocyte lysate (Fig. 2 , lane 3) that comigrated with the polypeptide synthesized in vitro from the G ori ORF, supporting the conclusion FIG. 1. Construction of BHV-1 recombinants. The schematic representation of the prototype orientation of the BHV-1 genome is shown above the HindIII restriction fragment map of BHV-1 strain Schönböken (7, 27) . The wild-type HindIII L fragment is enlarged, and the location and direction of transcription of genes encoding the putative protein kinase (PK) and glycoproteins G (gG), D (gD), I (gI), and E (gE) are indicated by arrows (15, 25, 40, 45) . Relevant restriction enzyme cleavage sites are marked. The respective HindIII fragment of the gD Ϫ lacZ ϩ mutant BHV-1/80-221 is depicted below. The location and direction of transcription of the lacZ cassette (dotted area, not drawn to scale) that replaces the gD ORF is indicated by an arrow. Underneath, a diagram of the integration fragment contained in the recombination vectors is shown. The gD TATA and gD poly(A) segments indicate BHV-1 sequences representing the gD promoter and the gD polyadenylation signal, respectively, which provide homologous regions for recombination. In this study, transcription of the BRSV G ori or G syn ORF (BRSVG ORF) was directed by the MCMV ie1 enhancer-promoter element (6) in transient-expression experiments or by the MCMV e1 promoter (2) in recombinant BHV-1 infected cells. Transcription of the BHV-1 gD ORF which is followed by the MCMV ie2 poly(A) signal (28) is under the control of the authentic gD promoter.
FIG. 2.
Cell-free translation of cRNAs encompassing the BRSV G ori or G syn ORF. 35 S-labeled proteins translated in vitro from RNA transcribed in vitro from plasmids pSPG ori (lane 2) or pSPG syn (lane 3) were size separated in SDS-10% polyacrylamide gels and visualized by fluorography. In lane 1, proteins synthesized from RNA transcribed from pSPG ori antisense to the BRSV G glycoprotein ORF were separated. The apparent molecular mass of the translation products, indicated in kilodaltons on the left, was calculated from the migration of 14 C-methylated protein molecular mass standards run on the same gel. that the 31-kDa protein represents the primary translation product encoded by the BRSV G glycoprotein ORF.
Integration of the BRSV-G syn ORF into the genome of BHV-1/80-221. Recombination plasmid pROMeG syn was cotransfected with purified BHV-1/80-221 DNA into MDBK cells, and the recombinant virus, BHV-1/eG syn , was isolated as described above for BHV-1/eG ori . To demonstrate integration of the expression cassettes into the genomes of the respective viruses, MDBK cells were infected with BHV-1/eG ori , BHV-1/eG syn , and BHV-1/80-221, phenotypically complemented by propagation on gD-expressing cells (8) . Whole-cell DNA was prepared 20 h postinfection (p.i.), cleaved with HindIII, transferred to nitrocellulose filters after size separation in 0.6% agarose gels, and hybridized to G syn -, G ori -, and lacZ-specific 32 P-labeled DNA fragments. The sizes of the fragments that hybridized to the respective probes were as expected (data not shown). We concluded that BHV-1/eG ori and BHV-1/eG syn were generated by homologous recombination as envisaged.
Transcription of the BRSV G ori and BRSV G syn ORFs in recombinant BHV-1-infected cells.
To test for transcription from the recombinant BRSV G genes, MDBK cells were infected with BHV-1/eG syn (Fig. 4, lanes 1, 3, 5, and 7) and BHV-1/eG ori (lanes 2, 4, 6, and 8). Cytoplasmic RNA was isolated at 6 h p.i., size separated by agarose gel electrophoresis, and transferred to nitrocellulose filters. A 32 P-labeled DNA probe representing the BRSV G syn ORF detected an RNA of 1.3 kb after infection with BHV-1/eG syn (lane 1) and, after extended exposure, a transcript of 1.8 kb (lane 5) whose synthesis is initiated approximately 500 bp upstream from the MCMV e1 promoter (13) . Even after a longer exposure, G ori ORF-specific transcripts of the expected size were not detected (lanes 2 and 6). The faint smear in lane 6 might indicate the presence of fragmented G ori RNA. Hybridization of the filters with 32 P-labeled DNA encompassing the BHV-1 gD ORF showed that comparable amounts of gD mRNA were detected in BHV-1/eG syn -infected cells (lanes 3 and 7) and BHV-1/ eG ori -infected cells (lanes 4 and 8) , demonstrating that the (lanes 1, 3, 5, and 7) and BHV-1/ eG ori (lanes 2, 4, 6, and 8) was prepared at 6 h p.i., and 5-g samples were transferred to nitrocellulose after 1% agarose gel electrophoresis. The filters were hybridized to 32 P-labeled DNA from the BRSV-G syn ORF (lanes 1 and 5) , the BRSV-G ori ORF (lanes 2 and 6) , and the BHV-1 gD ORF (lanes 3, 4, 7, and 8). Bound radioactivity was visualized by autoradiography. Lanes 5 to 8 are longer exposures of lanes 1 to 4. Transcript sizes are indicated in kilobases. absence of stable transcripts from the BRSV G ori ORF was not due to degradation of the RNA from BHV-1/eG ori -infected cells. Substantially the same results were obtained with RNAs isolated 16 h after infection with BHV-1/eG syn and BHV-1/ eG ori in the absence or presence of phosphonoacetic acid (data not shown).
To support the assumption that transcripts from the BRSV G ori ORF are unstable in BHV-1/eG ori -infected cells, elongation of initiated transcripts in BHV-1/eG ori -and BHV-1/eG syninfected MDBK cells was analyzed by nuclear runoff transcription assays. 32 P-labeled RNA, synthesized in nuclei isolated at 6 h p.i., was hybridized to DNA from the plasmid vector pSP73 or from plasmids pSPG ori , pSPG syn , or pSPgD dotted onto nitrocellulose membranes. Elongation of RNA from both BRSV G ORFs was detected (data not shown). The ratio of bound radioactivity between the respective BRSV G ORFs and the corresponding BHV-1 gD ORFs was 1.7 with RNA from BHV-1/eG ori -infected cells and 2.1 with RNA from BHV-1/eG syn -infected cells, demonstrating that the G ori ORF was transcribed in BHV-1/eG ori -infected cells. These results are in accordance with the conclusion that BHV-1-expressed BRSV G ori RNAs are unstable in the nuclei of infected cells.
Identification and characterization of BHV-1-expressed BRSV G glycoprotein. To test for the expression of the BRSV G glycoprotein in BHV-1/eG syn -infected cells, BRSV G glycoprotein-specific MAb 20 and a polyclonal antiserum (anti-VacG syn ), raised in rabbits after infection with G syn -expressing recombinant vaccinia virus, were used to stain wild-type BHV-1 strain Schönböken (BHV-1/Schö)-, BHV-1/eG syn -, or BHV-1/eG ori -induced plaques by indirect immunofluorescence. The cultures were fixed 2 days after infection and incubated with the BHV-1 gD-specific MAb 21/3/3, MAb 20, or the anti-VacG syn serum. Antibodies bound on the cell surface were visualized by using DTAF-conjugated anti-species immunoglobulin G and fluorescence microscopy. As shown in Fig. 5 , MAb 20 and the anti-VacG syn serum bound only to cells in plaques generated by BHV-1/eG syn whereas MAb 21/3/3 reacted with gD on the surface of cells infected with BHV-1/ Schö, BHV-1/eG syn , and BHV-1/eG ori . The conclusion that the BRSV G syn ORF-encoding protein is expressed on the surface of BHV-1/eG syn -infected cells was also demonstrated by flow cytometry with living cells and the same antibodies as above (data not shown).
To further characterize the BRSV G syn ORF-encoded gene product, proteins from infected cells (Fig. 6, lanes 1 to 4) , purified virions (lanes 5 to 7), and the cell culture medium from BHV-1/eG syn -infected cells (lane 8) were analyzed by immunoblotting because MAb 20 and the anti-VacG syn serum did not work for immunoprecipitation. MAb 20 did not specifically bind to proteins from cells infected with BHV-1/Schö (Fig. 6, lane 1) and BHV-1/eG ori (lane 2) or to proteins from purified BHV-1/Schö and BHV-1/eG ori virions (lanes 5 and 6) but reacted strongly with proteins with apparent molecular masses of 38 and 43 kDa from BHV-1/eG syn -infected cells (lane 3). In addition, several weaker-staining bands ranging in size from 70 to about 100 kDa were detected. To elucidate possible precursor-product relationships among the MAb 20reactive polypeptides, BHV-1/eG syn -infected cells were incubated for 2 h with cycloheximide (final concentration, 100 g per ml) before lysis to inhibit de novo protein synthesis. This treatment resulted in a considerable decrease in the signal at 38 kDa and a slight reduction in the band intensity of the signal at 43 kDa, whereas the bands corresponding to larger proteins increased in size and abundance (Fig. 6, lane 4) . Prolongation of the cycloheximide incubation time did not significantly alter this pattern but resulted in a decrease in the intensities of all bands (data not shown). Among proteins from purified virus particles, MAb 20 bound only to polypeptides from BHV-1/ eG syn virions which migrated as a diffuse band with an apparent molecular mass between 70 and 120 kDa (lane 7). No MAb 20-reactive proteins were detected in the medium of BHV-1/ eG syn -infected cells (lane 8). Identical results were obtained with the anti-VacG syn serum and BRSV G glycoprotein-specific MAb 57 (9) . The latter immunoprecipitated the large molecules but not the 38-and 43-kDa proteins from cells infected with BHV-1/eG syn in the presence of [ 35 S]methionine and [ 35 S]cysteine. From these results, we conclude that the 38and 43-kDa proteins represent BRSV G glycoprotein precursor molecules which are subsequently modified to the large form, which is also associated with BHV-1/eG syn virions.
The carbohydrate composition of virus particle-associated BRSV G glycoprotein was analyzed by incubation of purified BHV-1/eG syn virions with glycosidase F, neuraminidase, and neuraminidase together with O-glycosidase followed by immunoblotting after SDS-PAGE with MAb 20 (Fig. 7a) or a polyclonal rabbit serum raised against purified BHV-1 gD (Fig. 7b ) to monitor the reactions. According to the enzymes used, the electrophoretic mobilities of virion-associated gD increased as expected (41) , and no differences were detected in comparison to the reaction products of immunoprecipitated virion gD (Fig.  7b and c) , indicating the presence of sufficient enzymatic activity for complete deglycosylation within the respective probes. The BRSV G glycoprotein molecules appeared unaffected after incubation with neuraminidase (Fig. 7a, lane 2) and exhibited an increased electrophoretic mobility following digestion with neuraminidase and O-glycosidase (lane 3) or N-glycosidase F (lane 4), which demonstrates the presence of O-and N-linked carbohydrates in the virion-associated BRSV G glycoprotein. However, digestion products obtained after incubation of the virion proteins with neuraminidase and Oglycosidase migrated slower and were more diffuse, as expected for the only N-glycosylated form. Whether this discrep-ancy is due to additional modifications, the presence of O-glycosidase-resistant O-linked carbohydrates (22) , or incomplete removal of O-linked glycans due to specifics of the BRSV G glycoprotein has to be analyzed.
Virus neutralization assays. The immunoblot analysis in Fig.  6 indicated that BHV-1/eG syn virus particles contain the BRSV G glycoprotein and therefore should be susceptible to inactivation by BRSV G glycoprotein-specific antibodies. BHV-1/ eG ori and BHV-1/eG syn virions were tested for complementdependent and -independent neutralization by MAb 57, the anti-VacG syn serum, and the anti-BRSV serum 2106 (9) . With complement, MAb 57, which had no effect on the infectivity of BHV-1/eG ori (data not shown), reduced the number of BHV-1/eG syn -induced plaques to 52% at a final dilution of 1:25. The anti-VacG syn serum specifically neutralized BHV-1/eG syn in the presence of complement to 50% neutralization at a dilution of about 1:1,000 ( Fig. 8) . No activity was detectable without complement (data not shown). The BHV-1/eG syn -neutralizing activity of anti-BRSV serum 2106 was weak in the absence of complement and more pronounced after the addition of complement. Both polyclonal sera had no significant effect on the infectivity of BHV-1/eG ori (Fig. 8 ) and BHV-1/ Schö (data not shown).
DISCUSSION
Analysis of the expression from the authentic BRSV G glycoprotein ORF after infection of cells with BHV-1/eG ori indicated that the transcripts are unstable in the nucleus. We assumed that this was due to the nucleotide sequence of the RNA, which might contain signals that do not interfere with the stability of the RNA in the cytoplasm of cells infected with BRSV or recombinant vaccinia virus expressing the BRSV G glycoprotein (24) but result in degradation of the transcripts in the nucleus. Therefore, the complete BRSV G glycoprotein ORF was reconstructed by using synthetic oligonucleotides. The codon usage of the modified ORF was adjusted to that of BHV-1 gD, resulting in an increase of the GϩC content from 42 to 62%, and the introduction of putative splice donor signals (30) was avoided. The synthetic ORF was inserted into the genome of BHV-1 under the control of the MCMV e1 promoter (2, 21) , and analysis of the gene products in BHV-1/ eG syn -infected cells demonstrated transcription of mRNA, which was translated into proteins recognized by BRSV G glycoprotein-specific MAb 20 and the anti-VacG syn serum. Although we did not attempt to delineate sequence motifs leading to instability of the G ori transcripts in the nucleus, our results strongly suggest their existence, which might also explain the failure to express the authentic ORF encoding BRSV fusion protein F by BHV-1 (13) . Introduction of a series of single restriction enzyme cleavage sites into the G syn ORF will be helpful in identifying sequence elements that prevent the generation of mRNA from the genomic BRSV G glycoprotein ORF, which may be beneficial for the development of systems for the expression of RNA virus genes in the nuclei of mammalian cells.
The BRSV G glycoprotein is a type II membrane glycoprotein with a 37-amino-acid N-terminal cytoplasmic domain followed by 29 hydrophobic amino acids representing the transmembrane region. The remaining 191 amino acids are mainly hydrophilic and constitute the extracellular domain (24). Among BHV-1/eG syn -infected cell proteins, MAb 20, MAb 57, and the anti-VacG syn serum detected proteins with apparent molecular masses of 38, 43, and 70 to 120 kDa. Inhibition of de novo protein synthesis by cycloheximide resulted in a decrease of the signals generated by the 38-and 43-kDa proteins and a concomitant increase in intensity and size of the large-protein band. Although the exact precursor-product relationship awaits clarification, we assume that the 38-and 43-kDa proteins represent precursor molecules of the mature BRSV G glycoprotein. This assumption is in accordance with results reported by Lerch et al. (24) , who demonstrated that in cells infected with a BRSV G glycoprotein-expressing recombinant vaccinia virus, two proteins which migrated with an apparent molecular mass of 43 kDa and as a broad band between 68 and 97 kDa specifically reacted with an anti-BRSV serum in immunoblots. They further provided evidence that the 43-kDa form represents a precursor containing only N-linked carbohydrates whereas the 68-to 97-kDa molecules constitute the mature N-and O-glycosylated BRSV G glycoprotein.
Expression of the BRSV G glycoprotein in BHV-1/eG syninfected cells was analyzed only by immunoblotting because the BRSV G glycoprotein-specific MAb 20 and the anti-VacG syn serum did not work for immunoprecipitation and MAb 57 precipitated only the mature glycoprotein after synthesis in the presence of [ 35 S]methionine and [ 35 S]cysteine (not shown). The observation that antibodies against the BRSV G glycoprotein bind in immunoblots but fail to immunoprecipitate the antigen is, although surprising, not without precedent and has also been reported by Lerch et al. (24) . The reason for this apparent paradox, however, remains unclear.
Immunofluorescence and flow cytometry (data not shown) with MAb 20 and the anti-VacG syn serum demonstrated that BHV-1/eG syn -infected cells expressed the BRSV G glycoprotein on the cell surface, and we conclude that it is tightly anchored in the cell membrane since no secreted molecules were found in the medium from BHV-1/eG syn -infected cultures. Thus, our results indicate Golgi processing and post-Golgi transport of the BHV-1/eG syn -encoded BRSV G glycoprotein to the cell surface, comparable to the situation in BRSV-or recombinant vaccinia virus-infected cells (24) .
Since alphaherpesviruses probably do not encode type II glycoproteins, we investigated whether the BRSV G glycoprotein that presumably lacks any herpesvirus-specific targeting signals is incorporated into BHV-1 particles. Western blot analysis with MAb 20 revealed incorporation of the BRSV G glycoprotein into purified virus particles, and this was confirmed by the susceptibility of BHV-1/eG syn virions to neutralization by the anti-VacG syn serum, the anti-BRSV immune serum, and MAb 57 in the presence of complement. That these antibodies did not neutralize in the absence of complement was not too surprising, since it is unlikely that the BRSV G glycoprotein exhibits a biological function for the infectivity of BHV-1. In addition, flow cytometry demonstrated that MAb 20 and the anti-VacG syn serum bound to living cells infected with purified BHV-1/eG syn virions in the presence of cycloheximide to prevent de novo protein synthesis (13) . This further supports the conclusion that the orientation of the BRSV G glycoprotein within the viral envelope is correct.
To our knowledge, this is the first description of a class II membrane glycoprotein becoming incorporated into alphaherpesvirus virions. The presence of the BRSV G glycoprotein in the given background of BHV-1/eG syn exerted only a slight influence on the entry of virions into target cells in comparison to the situation for wild-type BHV-1 (data not shown). Although no repaired viruses were included in this study, we believe that it is reasonable to assume that BRSV G glycoprotein does not significantly interfere with the envelope structures required for the initial steps of the BHV-1 infection.
This study has practical implications for herpesvirus-based vector vaccine development: (i) it indicates that modification of RNA virus genes may be required for efficient expression, and (ii) it raises the possibility of targeting foreign antigens as class II membrane (glyco)proteins into the envelope of herpesvirus virions, which might be important when booster vaccinations with live recombinant viruses are inefficient due to existing immunity to the vector, a situation observed with recombinant vaccinia viruses (13, 26) .
